Skip to content
Study details
Enrolling now

NTS-WBRT in Brain Metastases

Massachusetts General Hospital
NCT IDNCT05013892ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

41

Study length

about 5.9 years

Ages

18+

Locations

1 site in MA

What this study is about

Researchers are testing the quality of life and symptom burden in adults receiving normal tissue sparing whole brain radiation therapy (NTS-WBRT) along with standard care medication. The trial will last for approximately 2 years.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive NTS-WBRT (normal tissue sparing whole brain radiation therapy)
  • 2.Take Memantine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

memantine

Endpoints

Primary: Change in Patient Reported Quality of Life for NTS-WBRT (normal tissue sparing whole brain radiation therapy), Change in Patient Reported Symptom Burden for NTS-WBRT (normal tissue sparing whole brain radiation therapy)

Secondary: Change in Fatigue between NTS-WBRT+SIB and NTS-WBRT, Intracranial- Progression Free Survival (PFS) between NTS-WBRT+SIB and NTS-WBRT, Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0, Overall survival (OS) between NTS-WBRT+SIB and NTS-WBRT

Procedures

radiation